Journals / Turkish Journal of Hematology / 2012 / Cilt: 29 - Sayı: 1

Kronik miyelositer lösemi ve multipl miyelom olgularındaki kemik iliği kaynaklı hücrelerde, hücre siklusu düzenleyicilerinin (siklinler ve siklin bağımlı kinaz inhibitörleri) akım sitometrik olarak değerlendirilmesi

Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma

Pages
17–27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This finding may increase our understanding of the mechanisms involved in the etiopathogenesis of hematological malignancy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to use flow cytometry to analyze the expression of cell cycle-regulating elements with low and high proliferative signatures in patients with malignant diseases.
📊
Key Findings & Data:Material and Methods: Cyclin D, E, A, and B, and cyclin-dependent kinase inhibitor (CDKI) p16 and p21 levels were measured via flow cytometry in patients with chronic myeloid leukemia (CML) (n = 16) and multiple myeloma (MM) (n = 13), and in controls (n = 15).
💡
Conclusion & Impact:This finding may increase our understanding of the mechanisms involved in the etiopathogenesis of hematological malignancy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to use flow cytometry to analyze the expression of cell cycle-regulating elements with low and high proliferative signatures in patients with malignant diseases. Material and Methods: Cyclin D, E, A, and B, and cyclin-dependent kinase inhibitor (CDKI) p16 and p21 levels were measured via flow cytometry in patients with chronic myeloid leukemia (CML) (n = 16) and multiple myeloma (MM) (n = 13), and in controls (n = 15). Results: The distributions of the cell cycle S phase were 10, 63%, 6, 72% and 3, 59%; for CML, MM and control patients, respectively. Among all the cyclins expressed during the S phase, cyclin D expression was the lowest in the CML patients. Distribution of cyclins and CDKIs during the G2/M phase was similar in the MM and control groups, whereas cyclin expression was similar during all 3 phases in the MM and CML groups. Conclusion: Elevated cyclin expression during cell cycle phases in the CML and MM patients was not associated with elevated CDKI expression. This finding may increase our understanding of the mechanisms involved in the etiopathogenesis of hematological malignancy.

Özet

Amaç: Bu çalışmanın amacı, yüksek ve düşük proliferasyon hızına sahip malign hastalıklarda, hücre siklusunu düzenleyen faktörlerin flow sitometrik olarak analiz edilmesidir. Gereç ve Yöntemler: Kronik miyelositer lösemi (KML) (n=16), Multipl Miyelom (MM) (n=13) ve kontrol (n=15) olgularında siklin D, E, A, B ve siklin bağımlı kinaz inhibitörü (SBKİ) p16, p21 düzeyleri akımsitometrik yöntemle ölçülmüş ve değerlendirilmiştir. Bulgular: KML, MM ve kontrol olgularındaki S evresi dağılımı sırasıyla % 10, 63; % 6, 72 ve % 3, 59 olarak saptanmıştır. KML grubunda siklin D ekspresyonu, S evresindeki diğer siklinlere göre en düşük düzeyde bulunmuştur. G2/M evresinde, MM ve kontrol gruplarındaki siklin ve SBKİ düzeyleri birbirleriyle benzer saptanırken, MM ve KML gruplarının her üç evresindeki siklin ekspresyonları ise paralel bulunmuştur. Sonuç: Kontrol grubuyla karşılaştırıldığında hasta gruplarında, siklin ekspresyonlarının artışına SBKİ düzeylerinin artışının eşlik etmediği saptanmıştır. Bu bulgu, belki de hematolojik malign hastalıkların etyopatogenezinin açıklanmasına katkıda bulunabilecektir.

🔖

Cite This Article

TOPRAK, K. S., DALVA, K., KIZIL, M. Ç., KURŞUN, N., BEKSAÇ, M. (2012). Kronik miyelositer lösemi ve multipl miyelom olgularındaki kemik iliği kaynaklı hücrelerde, hücre siklusu düzenleyicilerinin (siklinler ve siklin bağımlı kinaz inhibitörleri) akım sitometrik olarak değerlendirilmesi. Turkish Journal of Hematology, Cilt: 29 - Sayı: 1, 17–27. https://ajindex.com/articles/412660

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Vermeulen K, Berneman ZN, Van Bockstaele DR: Cell cycle and apoptosis. Cell Prolif 2003
  2. 175 2. Nakayama KI, Nakayama K: Ubiquitin ligases: Cell-cycle control and cancer. Nat Rev Cancer 2006
  3. 381 3. Golias CH, Charalabopoulos A, Charalabopoulos K: Cell proliferation and cell cycle control: A mini review. Int J Clin Pract 2004
  4. 1141 4. de Cárcer G, Pérez de Castro I, Malumbres M: Targeting cell cycle kinases for cancer therapy. Curr Med Chem 2007
  5. 985 5. Malumbres M, Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 2009
  6. 166 6. Echalier A, Endicott JA, Noble ME: Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochim Biophys Acta 2010
  7. 519 7. Budirahardja Y, Gönczy P: Coupling the cell cycle to development. Development 2009
  8. 2872 8. Stillman B: Cell cycle control of DNA replication. Science 1996
  9. 1664 9. Hunter T, Pines J: Cyclins and cancer. Cell 1991
  10. 1074 10. Sherr CJ: Cancer cell cycles. Science 1996
  11. 1677 11. Dickson MA, Schwartz GK: Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009
  12. 43 12. Cirstea D, Vallet S, Raje N: Future novel single agent and combination therapies. Cancer J 2009
  13. 518 13. Specht K, Haralambieva E, Bink K, Kremer M, Mandl- Weber S, Koch I, Tomer R, Hofler H, Schuuring E, Kluin PM, Fend F, Quintanilla-Martinez L: Different mechanism of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 2004
  14. 1126 14. Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK: Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest 2008
  15. 1764 15. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr: Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 2005
  16. 303 16. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen- Kiang S, Durie BGM, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H
  17. International Myeloma Working Group: Molecular classification of multiple myeloma: Spotlight review. Leukemia 2009
  18. 2221 17. Zang C, Liu H, W